Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
Fennec Pharmaceuticals announced that four independent studies evaluating PEDMARK will be presented at the 2026 ASCO Annual Meeting, expanding the evidence base for its use in adult and adolescent populations. The data includes a Phase 1 trial in metastatic germ cell tumors, a Phase 2/3 study in Japan showing significant hearing loss reduction in pediatric/AYA patients, and real-world case series in young adults and head and neck cancer patients.
Key figures
- Drug Name
- PEDMARK (sodium thiosulfate injection)
- Pediatric hearing loss reduction
- 16-24% vs 56-63% historical
- Adult gct hearing loss prevalence
- 75%
- Us annual platinum chemo patients
- 500,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.